ScholarLens Back to search
2019•PMCRequires access

Dietary Phosphorus and FGF23: Is More Restriction Better?

Kathleen M. Hill Gallant

Open publisher page 0 citations

Abstract

Patients with ESKD undergoing hemodialysis are at high risk for cardiovascular events, which have been associated with abnormal phosphate homeostasis. Hyperphosphatemia and elevated serum fibroblast growth factor 23 (FGF23) cause vascular calcifications and left ventricular hypertrophy, respectively

About this research paper

What this paper is about

Patients with ESKD undergoing hemodialysis are at high risk for cardiovascular events, which have been associated with abnormal phosphate homeostasis. Hyperphosphatemia and elevated serum fibroblast growth factor 23 (FGF23) cause vascular calcifications and left ventricular hypertrophy, respectively

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Patients with ESKD undergoing hemodialysis are at high risk for cardiovascular events, which have been associated with abnormal phosphate homeostasis. Hyperphosphatemia and elevated serum fibroblast growth factor 23 (FGF23) cause vascular calcifications and left ventricular hypertrophy, respectively

Key concepts: Hyperphosphatemia, Fibroblast growth factor 23, Internal medicine, Left ventricular hypertrophy, Medicine, Phosphate, Hemodialysis, Phosphorus

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Dietary Phosphorus and FGF23: Is More Restriction Better? — Research Paper | ScholarLens